Boya Bio-Pharmaceutical Proposed To Purchase 60.55% of Stock From Royal Bio Pharmaceutical

Boya Bio-Pharmaceutical proposed to purchase 60.55% of stock from other holders of Royal Bio Pharmaceutical. Boya Bio-Pharmaceutical is a medical company listed in 2012, mainly engaged in R&D, production and sales of biochemical drugs. As of now, Boya Bio-Pharmaceutical's products cover blood products, diabetes drugs, orthopedics, obstetric drugs and other fields.

Royal Bio Pharmaceutical was established in October 2002 and is mainly focusing on the development, production and marketing of vaccines. Its main products include group A group C meningococcal polysaccharide conjugate vaccine and bivalent renal syndrome hemorrhagic fever inactivated vaccine. Among them, group A group C meningococcal polysaccharide conjugate vaccine is used to prevent epidemic cerebrospinal meningitis in children; bivalent renal syndrome hemorrhagic fever inactivated vaccine is used to prevent hemorrhagic fever with renal syndrome.

Boya Bio-Pharmaceutical believes this purchase could expand their business into the vaccines industry since according to the government statistics, the total size of Chinese vaccine market has increased from 99.9 billion RMB in 2013 to 25.3 billion RMB in 2017, and is expected to increase to 100.9 billion yuan in 2030.